The South Korean pharma industry has gone through vast changes in the past decade. The sector has shifted its focus more to the development of new drugs and away from generics, increased the development of biologics/biosimilars and become more active in seeking open innovation and pursuing entry into global markets to ensure growth.
The typically generics-focused domestic pharma environment changed particularly after the country reached free trade agreements with the US, EU and China starting in 2007